Hello, everyone, and how are you today? We are doing just fine, thank you, courtesy of a warm and shiny sun enveloping the Pharmalot campus. The short people have left for their destinations — the local schoolhouse and gainful employment, respectively — and the official mascot is snoozing in his corner. As for us, we are already quite busy firing up the coffee kettle and foraging for interesting items. Speaking of which, here are a few tidbits to get you going this morning. Hope your day burns brightly and, as always, do stay in touch …

Bristol-Myers Squibb (BMY) and Starboard Value issued dueling presentations over the merits of the $74 billion bid the drug maker has made for Celgene (CELG). Bristol-Myers maintained that the deal would give the combined companies number-one positions in oncology and cardiovascular drug sales, while Starboard argued that Celgene is facing a “massive patent cliff” that will force it to replace about 60 percent of its revenues over the next seven years (here is the Bristol presentation and here is the Starboard presentation). Bristol shareholders vote on April 12.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy